SERETIDE INHALER inhalatsiooniaerosool, suspensioon Estonja - Estonjan - Ravimiamet

seretide inhaler inhalatsiooniaerosool, suspensioon

glaxosmithkline (ireland) limited - salmeterool+flutikasoon - inhalatsiooniaerosool, suspensioon - 25mcg+125mcg 1annus 120annus 1tk

Temybric Ellipta Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

temybric ellipta

glaxosmithkline trading services limited - flutikasoonfuroaat, umeklidiiniumbromiid, vilanterooltripenataat - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - temybric ellipta on näidustatud hooldus ravi täiskasvanud patsientidel, kellel on mõõdukas kuni raskekujuline krooniline obstruktiivne kopsuhaigus (copd), kes ei ole piisavalt töödeldud kombinatsiooniga inhaleeritava kortikosteroidi ja pika toimeajaga β2-agonist või kombinatsioon pikatoimeline β2-agonist ja pika toimeajaga muscarinic antagonist (toimete kohta sümptom kontrolli ja ennetamise ägenemised vt lõik 5.

Blenrep Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

blenrep

glaxosmithkline (ireland) limited - belantamab mafodotin - mitu müeloomit - antineoplastilised ained - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Libmeldy Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

libmeldy

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - muud närvisüsteemi ravimid - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

ZINNAT õhukese polümeerikattega tablett Estonja - Estonjan - Ravimiamet

zinnat õhukese polümeerikattega tablett

ideal trade links uab - tsefuroksiim - õhukese polümeerikattega tablett - 250mg 10tk

ZINNAT õhukese polümeerikattega tablett Estonja - Estonjan - Ravimiamet

zinnat õhukese polümeerikattega tablett

ideal trade links uab - tsefuroksiim - õhukese polümeerikattega tablett - 500mg 10tk

ZINNAT õhukese polümeerikattega tablett Estonja - Estonjan - Ravimiamet

zinnat õhukese polümeerikattega tablett

lex ano uab - tsefuroksiim - õhukese polümeerikattega tablett - 500mg 14tk

Xevudy Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

xevudy

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - suguhormoonid ja immunoglobuliinid, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.

PIRFENIDONE TEVA õhukese polümeerikattega tablett Estonja - Estonjan - Ravimiamet

pirfenidone teva õhukese polümeerikattega tablett

teva gmbh - pirfenidoon - õhukese polümeerikattega tablett - 801mg 252tk; 801mg 84tk

PIRFENIDONE TEVA õhukese polümeerikattega tablett Estonja - Estonjan - Ravimiamet

pirfenidone teva õhukese polümeerikattega tablett

teva gmbh - pirfenidoon - õhukese polümeerikattega tablett - 267mg 252tk